CytomX/$CTMX
1D1W1MYTD1Y5YMAX
Capital at risk
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
- Ticker
- $CTMX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 69
- Headquarters
- South San Francisco, United States
- Website
- www.cytomx.com
CytomX Metrics
BasicAdvanced
$573M
-
-$0.45
2.14
-
Price and volume
Market cap
$573M
Beta
2.14
52-week high
$8.21
52-week low
$2.60
Average daily volume
4M
Financial strength
Current ratio
9.361
Quick ratio
9.264
Long term debt to equity
0.014
Total debt to equity
0.019
Profitability
EBITDA (TTM)
-86.211
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-435.19%
Operating margin (TTM)
-476.17%
Effective tax rate (TTM)
-0.29%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-19.58%
Return on equity (TTM)
-37.75%
Valuation
Price to revenue (TTM)
26.287
Price to book
1.9
Price to tangible book (TTM)
1.91
Price to free cash flow (TTM)
-5.833
Free cash flow yield (TTM)
-17.14%
Free cash flow per share (TTM)
-0.451
Growth
Revenue change (TTM)
-87.03%
Earnings per share change (TTM)
-193.01%
3-year revenue growth (CAGR)
-38.71%
10-year revenue growth (CAGR)
7.07%
3-year earnings per share growth (CAGR)
-10.84%
10-year earnings per share growth (CAGR)
-14.52%
What the Analysts think about CytomX
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
Analyst projections of the future price of CytomX stock.
Bulls say / Bears say
Varseta-M has produced encouraging early clinical activity in heavily pre-treated colorectal cancer, with management reporting confirmed response rates of 32% at 10 mg/kg and 20% at 8.6 mg/kg, plus preliminary progression-free survival of 6.8 to 7.1 months. That gives CytomX a credible basis for its planned registrational study, although the evidence is still from Phase 1. (StockAnalysis)
The FDA granted Fast Track designation to Varseta-M for relapsed/refractory metastatic colorectal cancer, and CytomX plans to start a potential monotherapy registrational study in the first half of 2027. This could shorten regulatory interaction and gives investors a defined near-term development catalyst. (GlobeNewswire)
CytomX ended the second quarter with $330.3 million in cash, cash equivalents and investments and expects funding into at least the second half of 2028. Its expanded Regeneron collaboration also delivered a $37 million target-selection payment and could generate up to about $4 billion in future milestones, reducing near-term financing pressure. (CytomX Therapeutics, BioSpace)
Varseta-M remains a Phase 1 asset and its first registrational study has not started; the crucial overall-survival evidence is only due in a later-2026 update. Early response and progression-free-survival results may not predict success in a pivotal trial or approval. (CytomX Therapeutics)
Tolerability and dose selection are not fully resolved. CytomX said heavier patients had higher exposure and a tougher safety experience, so it changed to adjusted ideal body-weight dosing and added prophylaxis to manage diarrhoea; the chosen dose and the durability of this improvement still need confirmation. (StockAnalysis)
The operating model is becoming more dependent on financing and milestone income: second-quarter revenue fell to $1.4 million from $18.7 million a year earlier as older collaborations wound down, while the company reported a $250 million equity offering in March. The long cash runway therefore came partly through substantial shareholder dilution rather than product revenue. (StockTitan, CytomX Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
CytomX Financial Performance
Revenues and expenses
CytomX Earnings Performance
Company profitability
Upcoming events
No upcoming events
CytomX News
AllArticlesVideos
Funds containing CytomX
AllUSDGBPEUR
Fund name | Fund size | $CTMX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.